Recent

% | $
Quotes you view appear here for quick access.

công ty Affymax Message Board

  • wildbill400 wildbill400 Apr 16, 2013 8:08 AM Flag

    John Orwin speaks and said this-

    It appears that in the rare cases that have been reported thus far, serious hypersensitivity is a first-dose phenomenon and has only been reported with intravenous administration of the drug. In the post-marketing setting, there have been no reports of such reactions following subsequent dosing in patients who have completed their dialysis session or in patients receiving the drug subcutaneously, although the subcutaneous patient numbers are limited. (means Omontys is not the problem. we are going to $10.00)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AFFY
0.10+0.0050(+5.26%)Jul 1 3:20 PMEDT